Real-World Treatment Study of Koselugo (Selumetinib)

Status Not yet recruiting

Clinical Trial Summary

As part of a post-approval commitment, the Korean health authority requests a study to characterize safety and effectiveness in patients treated with Koselugo (Selumetinib), an oral selective inhibitor of MAPK kinase (MEK) 1 and 2, by physicians in routine clinical practice settings. This study is designed to assess the known safety profile or identify previously unsuspected adverse reactions and evaluate the effectiveness of Koselugo under conditions of routine daily medical practice in Korea. This study will provide information on the Korean patient population that is treated with the study drug.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT06360406
Study type	Observational
Source	AstraZeneca
Contact	AstraZeneca Clinical Study Information Center
Phone	1-877-240-9479
Email	information.center@astrazeneca.com
Status	Not yet recruiting
Phase
Start date	June 1, 2024
Completion date	September 30, 2031

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT01362803` - AZD6244 Hydrogen Sulfate for Children With Nervous System Tumors	Phase 1/Phase 2
Completed	`NCT00352599` - Trial to Evaluate the Safety of Lovastatin in Individuals With Neurofibromatosis Type I (NF1)	Phase 1
Completed	`NCT05005845` - NFX-179 Topical Gel Treatment for Adults With Neurofibromatosis 1 (NF1) and Cutaneous Neurofibromas (cNF)	Phase 2
Completed	`NCT03531814` - Medication Adherence in Children, Adolescents and Adults With Neurofibromatosis Type 1(NF1) on Clinical Treatment Trials	N/A
Completed	`NCT00846430` - Medical Treatment of "High-Risk" Neurofibromas	Phase 2
Completed	`NCT03433183` - SARC031: MEK Inhibitor Selumetinib (AZD6244) in Combination With the mTOR Inhibitor Sirolimus for Patients With Malignant Peripheral Nerve Sheath Tumors	Phase 2
Recruiting	`NCT05331105` - HL-085 in Adults With Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas	Phase 2
Completed	`NCT03310996` - Non-invasive Stimulation in Neurofibromatosis Type 1	N/A
Recruiting	`NCT03406208` - Resiliency Training for Adults With Neurofibromatosis Via Live Videoconferencing	N/A
Recruiting	`NCT04750928` - Cyclin-Dependent Kinase (CDK)4/6 Inhibitor Abemaciclib for Neurofibromatosis Type I (NF1) Related Atypical Neurofibromas	Phase 1/Phase 2
Not yet recruiting	`NCT06262113` - A Decentralized Clinical Trial to Promote Evidence-Based Care for Underserved Patients With Neurofibromatosis 1	N/A
Active, not recruiting	`NCT04924608` - Efficacy and Safety of Selumetinib in Adults With NF1 Who Have Symptomatic, Inoperable Plexiform Neurofibromas	Phase 3
Recruiting	`NCT02544022` - Development and Validation of Patient Reported Outcome (PRO) Measures for Individuals With Neurofibromatosis 1 (NF1) and Plexiform Neurofibromas (pNFs)
Recruiting	`NCT04941027` - Evaluating Genetic Modifiers of Cutaneous Neurofibromas in Adults With Neurofibromatosis Type 1
Completed	`NCT02153931` - Internet Support Group for Parents of a Child With Neurofibromatosis Type 1
Completed	`NCT05196854` - Clinical Hypnosis and Home Blood Pressure Monitoring in Children With Neurofibromatosis Type 1	N/A
Active, not recruiting	`NCT01650142` - Modifying Genes in Neurofibromatosis 1	N/A
Completed	`NCT05377008` - Intervention Effectiveness on the Neurocognitive Functioning of Children and Adolescents With Neurofibromatosis Type 1	N/A
Completed	`NCT04879160` - Systematically Assessing Changes in Plexiform Neurofibroma Related Disfigurement From Photographs of Subjects With Neurofibromatosis Type 1 on a Phase 2 Clinical Trial
Recruiting	`NCT05735717` - MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies	Phase 2